RGEN - Repligen EPS beats by $0.21 beats on revenue

Repligen (RGEN): Q4 Non-GAAP EPS of $0.52 beats by $0.21; GAAP EPS of $0.36 beats by $0.19.Revenue of $108.64M (+56.4% Y/Y) beats by $14.7M.FISCAL YEAR 2021 GUIDANCE:  Total revenue is expected to be in the range of $500-$525 million ($459.5M consensus), reflecting overall revenue growth of 37%-43% as reported and at constant currency and organic growth of 26%-33%.Revenue contribution from COVID-related programs are expected to be in the range of $90-$100 million, representing incremental COVID related revenue of $44-$54 million and 12%-15% points of overall revenue growth. Incremental acquisition-related revenue is expected to be in the range of $37-$40 million, representing 10%-11% points of overall revenue growth.Gross margin is expected to be 57%-58% on both a GAAP and non-GAAP basis.Income from operations is expected to be in the range of $103-$109 million on a GAAP basis. Adjusted (non-GAAP) income from operations is expected to be in the range of $134-$140

For further details see:

Repligen EPS beats by $0.21, beats on revenue